{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T06:22:01Z","timestamp":1792304521979,"version":"4.4.0"},"reference-count":155,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T00:00:00Z","timestamp":1540857600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"DOI":"10.3389\/fphys.2018.01514","type":"journal-article","created":{"date-parts":[[2018,10,30]],"date-time":"2018-10-30T03:11:02Z","timestamp":1540869062000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":205,"title":["Diabetic Cardiomyopathy: Current and Future Therapies. Beyond Glycemic Control"],"prefix":"10.3389","volume":"9","author":[{"given":"Giulia","family":"Borghetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"von Lewinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Eaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Houser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,10,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1111\/dom.12881","article-title":"Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients.","volume":"19","author":"Al Jobori","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"B2","doi-asserted-by":"publisher","first-page":"H118","DOI":"10.1152\/ajpheart.00932.2010","article-title":"Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways.","volume":"300","author":"Anderson","year":"2011","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00004872-200301000-00002","article-title":"Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes.","volume":"21","author":"Aronson","year":"2003","journal-title":"J. Hypertens."},{"key":"B4","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s10741-017-9666-8","article-title":"The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.","volume":"23","author":"Asleh","year":"2018","journal-title":"Heart Fail. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits.","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"B6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.jash.2014.01.007","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis.","volume":"8","author":"Baker","year":"2014","journal-title":"J. Am. Soc. Hypertens."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI60329","article-title":"Metabolic stress-induced activation of FoxO1 triggers diabetic cardiomyopathy in mice.","volume":"122","author":"Battiprolu","year":"2012","journal-title":"J. Clin. Invest."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003845","article-title":"Caveolin 1 modulates aldosterone-mediated pathways of glucose and lipid homeostasis.","volume":"5","author":"Baudrand","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.2337\/diabetes.53.12.3201","article-title":"Decreased sarcoplasmic reticulum activity and contractility in diabetic db\/db mouse heart.","volume":"53","author":"Belke","year":"2004","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1016\/j.jacc.2008.09.014","article-title":"The relationship of left ventricular mass and geometry to incident cardiovascular events: the MESA (Multi-Ethnic Study of Atherosclerosis) study.","volume":"52","author":"Bluemke","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10557-005-6892-4","article-title":"Glucagon like peptide-1 is protective against myocardial ischemia\/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model.","volume":"19","author":"Bose","year":"2005","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.metabol.2014.04.002","article-title":"Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity.","volume":"63","author":"Bostick","year":"2014","journal-title":"Metabolism"},{"key":"B14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/cvr\/cvq239","article-title":"Mitochondria in the diabetic heart.","volume":"88","author":"Bugger","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/ejhf.933","article-title":"The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors.","volume":"19","author":"Butler","year":"2017","journal-title":"Eur. J. Heart Fail."},{"key":"B16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrd2476","article-title":"Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials.","volume":"8","author":"Calcutt","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"B17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.RES.0000065620.39919.20","article-title":"A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes.","volume":"92","author":"Candido","year":"2003","journal-title":"Circ. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"14144","DOI":"10.1073\/pnas.0812536106","article-title":"The cAMP binding protein Epac regulates cardiac myofilament function.","volume":"106","author":"Cazorla","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2362.2006.01588.x","article-title":"Arterial stiffening and cardiac hypertrophy in a new rat model of type 2 diabetes.","volume":"36","author":"Chang","year":"2006","journal-title":"Eur. J. Clin. Invest."},{"key":"B20","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1046\/j.1365-201x.1999.00547.x","article-title":"Decrease in sodium-calcium exchange and calcium currents in diabetic rat ventricular myocytes.","volume":"166","author":"Chattou","year":"1999","journal-title":"Acta Physiol. Scand."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2337\/dc08-0118","article-title":"Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction.","volume":"31","author":"Chew","year":"2008","journal-title":"Diabetes Care"},{"key":"B22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cardiores.2007.06.022","article-title":"Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat.","volume":"76","author":"Connelly","year":"2007","journal-title":"Cardiovasc. Res."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-13875-2","article-title":"Circulating miR-19b and miR-181b are potential biomarkers for diabetic cardiomyopathy.","volume":"7","author":"Copier","year":"2017","journal-title":"Sci. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1093\/eurheartj\/ehv599","article-title":"MicroRNA profiling unveils hyperglycaemic memory in the diabetic heart.","volume":"37","author":"Costantino","year":"2016","journal-title":"Eur. Heart J."},{"key":"B25","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1023\/B:MCBI.0000038231.68078.4b","article-title":"Diabetic cardiomyocyte dysfunction and myocyte insulin resistance: role of glucose-induced PKC activity.","volume":"262","author":"Davidoff","year":"2004","journal-title":"Mol. Cell. Biochem."},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/srep37354","article-title":"Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes.","volume":"6","author":"de Gonzalo-Calvo","year":"2016","journal-title":"Sci. Rep."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-00070-6","article-title":"Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes.","volume":"7","author":"de Gonzalo-Calvo","year":"2017","journal-title":"Sci. Rep."},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00074","article-title":"microRNA in cardiovascular aging and age-related cardiovascular diseases.","volume":"4","author":"de Lucia","year":"2017","journal-title":"Front. Med."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00002","article-title":"Type 2 diabetes mellitus and cardiovascular disease: genetic and epigenetic links.","volume":"9","author":"De Rosa","year":"2018","journal-title":"Front. Endocrinol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"E630","DOI":"10.1152\/ajpendo.00109.2014","article-title":"Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium.","volume":"307","author":"DeNicola","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/aps.2011.149","article-title":"Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells.","volume":"33","author":"Ding","year":"2012","journal-title":"Acta Pharmacol. Sin."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1161\/CIRCHEARTFAILURE.112.000057","article-title":"Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure.","volume":"6","author":"dos Santos","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"B33","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1113\/expphysiol.2011.058271","article-title":"Left ventricle structural remodelling in the prediabetic Goto-Kakizaki rat.","volume":"96","author":"D\u2019Souza","year":"2011","journal-title":"Exp. Physiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.amjcard.2008.02.082","article-title":"Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population.","volume":"101","author":"Eguchi","year":"2008","journal-title":"Am. J. Cardiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"E1119","DOI":"10.1152\/ajpendo.00029.2008","article-title":"Regulation of cardiomyocyte hypertrophy in diabetes at the transcriptional level.","volume":"294","author":"Feng","year":"2008","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"B36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.yjmcc.2017.03.002","article-title":"miR-146a mediates inflammatory changes and fibrosis in the heart in diabetes.","volume":"105","author":"Feng","year":"2017","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cThrifty Substrate\u201d hypothesis.","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"B38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jacc.2009.12.003","article-title":"The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study.","volume":"55","author":"From","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1161\/01.RES.87.12.1123","article-title":"Myocardial cell death in human diabetes.","volume":"87","author":"Frustaci","year":"2000","journal-title":"Circ. Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.","volume":"348","author":"Gaede","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0002-9149(91)90716-X","article-title":"Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study).","volume":"68","author":"Galderisi","year":"1991","journal-title":"Am. J. Cardiol."},{"key":"B42","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0022-3565(24)36768-0","article-title":"Impaired contractile response to beta adrenoceptor stimulation in diabetic rat hearts: alterations in beta adrenoceptors-G protein-adenylate cyclase system and phospholamban phosphorylation.","volume":"282","author":"Gando","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1310265","article-title":"Diabetic cardiomyopathy: current approach and potential diagnostic and therapeutic targets.","volume":"2017","author":"Gilca","year":"2017","journal-title":"J. Diabetes Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1210\/jc.2007-1817","article-title":"Clinical review: the role of advanced glycation end products in progression and complications of diabetes.","volume":"93","author":"Goh","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B45","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes.","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1016\/S0140-6736(98)07037-8","article-title":"Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).","volume":"352","author":"Group","year":"1998","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-016-0489-z","article-title":"Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes.","volume":"16","author":"Habibi","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2174\/157016106777698469","article-title":"Role of oxidative stress in development of cardiovascular complications in diabetes mellitus.","volume":"4","author":"Haidara","year":"2006","journal-title":"Curr. Vasc. Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","article-title":"Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes.","volume":"31","author":"Hammoudi","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"B50","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1096\/fj.12-208991","article-title":"Insulin resistance improves metabolic and contractile efficiency in stressed rat heart.","volume":"26","author":"Harmancey","year":"2012","journal-title":"FASEB J."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1038\/sj.ejcn.1601464","article-title":"Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes.","volume":"56","author":"Hodgson","year":"2002","journal-title":"Eur. J. Clin. Nutr."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17122136","article-title":"Diabetic cardiomyopathy: does the type of diabetes matter?","volume":"17","author":"Holscher","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1152\/physrev.00034.2006","article-title":"The physiology of glucagon-like peptide 1.","volume":"87","author":"Holst","year":"2007","journal-title":"Physiol. Rev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1161\/CIRCRESAHA.117.312166","article-title":"Diabetes-induced cardiomyocyte passive stiffening is caused by impaired insulin-dependent titin modification and can be modulated by neuregulin-1.","volume":"123","author":"Hopf","year":"2018","journal-title":"Circ. Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21691401.2018.1478420","article-title":"Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.","volume":"6","author":"Hussain","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.pharmthera.2014.01.003","article-title":"Diabetic cardiomyopathy: mechanisms and new treatment strategies targeting antioxidant signaling pathways.","volume":"142","author":"Huynh","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.freeradbiomed.2013.02.021","article-title":"Targeting the upregulation of reactive oxygen species subsequent to hyperglycemia prevents type 1 diabetic cardiomyopathy in mice.","volume":"60","author":"Huynh","year":"2013","journal-title":"Free Radic. Biol. Med."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.2337\/db09-1456","article-title":"Cardiac-specific IGF-1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy.","volume":"59","author":"Huynh","year":"2010","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B60","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials.","volume":"12","author":"Inzucchi","year":"2015","journal-title":"Diab. Vasc. Dis. Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10741-013-9377-8","article-title":"Metabolic dysfunction in diabetic cardiomyopathy.","volume":"19","author":"Isfort","year":"2014","journal-title":"Heart Fail. Rev."},{"key":"B62","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nrendo.2015.216","article-title":"Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy.","volume":"12","author":"Jia","year":"2016","journal-title":"Nat. Rev. Endocrinol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1161\/HYPERTENSIONAHA.114.04737","article-title":"Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet.","volume":"65","author":"Jia","year":"2015","journal-title":"Hypertension"},{"key":"B64","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity.","volume":"122","author":"Jia","year":"2018","journal-title":"Circ. Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: the Framingham study.","volume":"34","author":"Kannel","year":"1974","journal-title":"Am. J. Cardiol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10741-017-9665-9","article-title":"Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.","volume":"23","author":"Kaplan","year":"2018","journal-title":"Heart Fail. Rev."},{"key":"B67","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1161\/CIRCRESAHA.110.239111","article-title":"Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling.","volume":"108","author":"Katare","year":"2011","journal-title":"Circ. Res."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2337\/diacare.22.9.1543","article-title":"Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.","volume":"22","author":"Kilhovd","year":"1999","journal-title":"Diabetes Care"},{"key":"B69","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure.","volume":"19","author":"Kim","year":"2013","journal-title":"Nat. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijcard.2016.02.146","article-title":"Effect of dipeptidyl peptidase-4 inhibitors on heart failure: a meta-analysis of randomized clinical trials.","volume":"211","author":"Kongwatcharapong","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower risk of heart failure and death in patients initiated on sodium-glucose cotransporter-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study (comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors).","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"B72","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.bcp.2017.08.021","article-title":"Dipeptidyl peptidase-4 independent cardiac dysfunction links saxagliptin to heart failure.","volume":"145","author":"Koyani","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1111\/j.1463-1326.2007.00670.x","article-title":"Interactions between microvascular and macrovascular disease in diabetes: pathophysiology and therapeutic implications.","volume":"9","author":"Krentz","year":"2007","journal-title":"Diabetes Obes. Metab."},{"key":"B74","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.ejrad.2017.08.033","article-title":"Perfusion CT - A novel quantitative and qualitative imaging biomarker in gastric cancer.","volume":"95","author":"Kruk-Bachonko","year":"2017","journal-title":"Eur. J. Radiol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1055\/s-2007-985823","article-title":"Apoptosis in patients with dilated cardiomyopathy and diabetes: a feature of diabetic cardiomyopathy?","volume":"39","author":"Kuethe","year":"2007","journal-title":"Horm. Metab. Res."},{"key":"B76","doi-asserted-by":"publisher","first-page":"R510","DOI":"10.1152\/ajpregu.00512.2011","article-title":"Intracardiac intracellular angiotensin system in diabetes.","volume":"302","author":"Kumar","year":"2012","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1016\/S0735-1097(01)01242-6","article-title":"The importance of age and obesity on the relation between diabetes and left ventricular mass.","volume":"37","author":"Kuperstein","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.2337\/diabetes.54.10.2988","article-title":"Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.","volume":"54","author":"Lankas","year":"2005","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B79","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/ncpcardio1347","article-title":"Interplay between impaired calcium regulation and insulin signaling abnormalities in diabetic cardiomyopathy.","volume":"5","author":"Lebeche","year":"2008","journal-title":"Nat. Clin. Pract. Cardiovasc. Med."},{"key":"B80","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3904\/kjim.2016.208","article-title":"Diabetic cardiomyopathy: where we are and where we are going.","volume":"32","author":"Lee","year":"2017","journal-title":"Korean J. Intern. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"R127","DOI":"10.1530\/EJE-17-0724","article-title":"MECHANISMS IN ENDOCRINOLOGY: diabetic cardiomyopathy: pathophysiology and potential metabolic interventions state of the art review.","volume":"178","author":"Levelt","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.yjmcc.2016.11.013","article-title":"Cardiac proteasome functional insufficiency plays a pathogenic role in diabetic cardiomyopathy.","volume":"102","author":"Li","year":"2017","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1161\/CIRCULATIONAHA.114.012285","article-title":"Upregulation of MG53 induces diabetic cardiomyopathy through transcriptional activation of peroxisome proliferation-activated receptor alpha.","volume":"131","author":"Liu","year":"2015","journal-title":"Circulation"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-9-76","article-title":"Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.","volume":"9","author":"Liu","year":"2010","journal-title":"Cardiovasc. Diabetol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ijcard.2017.02.126","article-title":"Perspectives on cardiovascular effects of incretin-based drugs: from bedside to bench, return trip.","volume":"241","author":"Luconi","year":"2017","journal-title":"Int. J. Cardiol."},{"key":"B86","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials.","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation"},{"key":"B87","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.lfs.2012.10.028","article-title":"Molecular and metabolic mechanisms of cardiac dysfunction in diabetes.","volume":"92","author":"Mandavia","year":"2013","journal-title":"Life Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1093\/eurjhf\/hft088","article-title":"Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders.","volume":"15","author":"Marfella","year":"2013","journal-title":"Eur. J. Heart Fail."},{"key":"B89","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"","journal-title":"N. Engl. J. Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"","journal-title":"N. Engl. J. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1161\/CIRCULATIONAHA.106.645614","article-title":"Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study.","volume":"116","author":"McGavock","year":"2007","journal-title":"Circulation"},{"key":"B92","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/nrendo.2012.140","article-title":"GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.","volume":"8","author":"Meier","year":"2012","journal-title":"Nat. Rev. Endocrinol."},{"key":"B93","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10741-012-9313-3","article-title":"Diabetic cardiomyopathy: pathophysiology and clinical features.","volume":"18","author":"Miki","year":"2013","journal-title":"Heart Fail. Rev."},{"key":"B94","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1161\/01.CIR.101.8.899","article-title":"Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model.","volume":"101","author":"Mizushige","year":"2000","journal-title":"Circulation"},{"key":"B95","doi-asserted-by":"crossref","first-page":"11880","DOI":"10.1016\/S0021-9258(18)67324-7","article-title":"Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing.","volume":"261","author":"Mojsov","year":"1986","journal-title":"J. Biol. Chem."},{"key":"B96","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1210\/er.2014-1035","article-title":"Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.","volume":"35","author":"Mulvihill","year":"2014","journal-title":"Endocr. Rev."},{"key":"B97","doi-asserted-by":"publisher","first-page":"742","DOI":"10.2337\/db15-1224","article-title":"Inhibition of dipeptidyl peptidase-4 impairs ventricular function and promotes cardiac fibrosis in high fat-fed diabetic mice.","volume":"65","author":"Mulvihill","year":"2016","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B98","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"","journal-title":"N. Engl. J. Med."},{"key":"B99","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/dom.12924","article-title":"Optimizing the analysis strategy for the CANVAS Program: a prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trials.","volume":"19","author":"Neal","year":"","journal-title":"Diabetes Obes. Metab."},{"key":"B100","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","article-title":"Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.","volume":"109","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","article-title":"Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.","volume":"356","author":"Nissen","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/978-3-319-22671-2_10","article-title":"microRNAs and cardiovascular remodeling.","volume":"888","author":"Ono","year":"2015","journal-title":"Adv. Exp. Med. Biol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and inhibition of sodium-hydrogen exchanger is a mechanism that links the pathophysiology and treatment of diabetes mellitus with that of heart failure.","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"key":"B104","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1161\/CIRCRESAHA.118.312673","article-title":"Do DPP-4 inhibitors cause heart failure events by promoting adrenergically mediated cardiotoxicity? Clues from laboratory models and clinical trials.","volume":"122","author":"Packer","year":"2018","journal-title":"Circ. Res."},{"key":"B105","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.tips.2018.02.010","article-title":"Emerging actors in diabetic cardiomyopathy: heartbreaker biomarkers or therapeutic targets?","volume":"39","author":"Palomer","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-05777-0","article-title":"Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors.","volume":"7","author":"Perge","year":"2017","journal-title":"Sci. Rep."},{"key":"B107","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome.","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur. Heart J."},{"key":"B109","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody.","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00300","article-title":"The big entity of new RNA world: long non-coding RNAs in microvascular complications of diabetes.","volume":"9","author":"Raut","year":"2018","journal-title":"Front. Endocrinol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11010-016-2729-7","article-title":"miR-30c and miR-181a synergistically modulate p53-p21 pathway in diabetes induced cardiac hypertrophy.","volume":"417","author":"Raut","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"B112","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/db13-1440","article-title":"Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.","volume":"63","author":"Richards","year":"2014","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B113","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/ijo.2012.170","article-title":"Myocardial substrate metabolism in obesity.","volume":"37","author":"Rider","year":"2013","journal-title":"Int. J. Obes."},{"key":"B114","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1089\/met.2015.0038","article-title":"The use of SGLT-2 inhibitors in type 2 diabetes and heart failure.","volume":"13","author":"Riggs","year":"2015","journal-title":"Metab. Syndr. Relat. Disord."},{"key":"B115","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.pharmthera.2009.08.001","article-title":"Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: no\u2217 and beyond.","volume":"124","author":"Ritchie","year":"2009","journal-title":"Pharmacol. Ther."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.yjmcc.2007.03.900","article-title":"The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo.","volume":"42","author":"Ritchie","year":"2007","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B117","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/2040622317735283","article-title":"Major adverse cardiovascular event reduction with GLP-1 and SGLT2 agents: evidence and clinical potential.","volume":"9","author":"Roder","year":"2018","journal-title":"Ther. Adv. Chronic Dis."},{"key":"B118","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis.","volume":"30","author":"Rubler","year":"1972","journal-title":"Am. J. Cardiol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.yjmcc.2015.12.011","article-title":"Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities.","volume":"90","author":"Russo","year":"2016","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7292564","article-title":"Cardiac resynchronization therapy outcomes in type 2 diabetic patients: role of MicroRNA changes.","volume":"2016","author":"Sardu","year":"","journal-title":"J. Diabetes Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/ijcp.12823","article-title":"Telemonitoring in heart failure patients treated by cardiac resynchronisation therapy with defibrillator (CRT-D): the telecart study.","volume":"70","author":"Sardu","year":"","journal-title":"Int. J. Clin. Pract."},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0554-2","article-title":"Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: impact on responders rate, and clinical outcomes.","volume":"16","author":"Sardu","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"B123","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ijcard.2016.06.208","article-title":"Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 Inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis.","volume":"220","author":"Savarese","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"B124","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1161\/CIRCULATIONAHA.107.188965","article-title":"Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group.","volume":"117","author":"Schocken","year":"2008","journal-title":"Circulation"},{"key":"B125","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B126","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.diabres.2009.10.007","article-title":"Global estimates of the prevalence of diabetes for 2010 and 2030.","volume":"87","author":"Shaw","year":"2010","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B127","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.yjmcc.2018.04.016","article-title":"Mitochondrial proteome disruption in the diabetic heart through targeted epigenetic regulation at the mitochondrial heat shock protein 70 (mtHsp70) nuclear locus.","volume":"119","author":"Shepherd","year":"2018","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B128","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1161\/CIRCULATIONAHA.112.096479","article-title":"Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions.","volume":"126","author":"Shigeta","year":"2012","journal-title":"Circulation"},{"key":"B129","doi-asserted-by":"publisher","first-page":"H150","DOI":"10.1152\/ajpheart.00737.2016","article-title":"Hyperglycemia induces defective Ca2+ homeostasis in cardiomyocytes.","volume":"312","author":"Sorrentino","year":"2017","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B130","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0008-6363(97)00047-3","article-title":"Regulation of energy substrate metabolism in the diabetic heart.","volume":"34","author":"Stanley","year":"1997","journal-title":"Cardiovasc. Res."},{"key":"B131","doi-asserted-by":"publisher","first-page":"H1361","DOI":"10.1152\/ajpheart.00454.2012","article-title":"Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice.","volume":"304","author":"Takahashi","year":"2013","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-017-0611-x","article-title":"Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?","volume":"16","author":"Tanaka","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1042\/CS20160491","article-title":"Are targeted therapies for diabetic cardiomyopathy on the horizon?","volume":"131","author":"Tate","year":"2017","journal-title":"Clin. Sci."},{"key":"B134","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jacc.2008.10.033","article-title":"Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.","volume":"53","author":"Timmers","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2018.00453","article-title":"Diabetic cardiomyopathy: impact of biological sex on disease development and molecular signatures.","volume":"9","author":"Toedebusch","year":"2018","journal-title":"Front. Physiol."},{"key":"B136","doi-asserted-by":"publisher","first-page":"2850","DOI":"10.1016\/j.jacc.2016.09.972","article-title":"The emerging role of metabolomics in the diagnosis and prognosis of cardiovascular disease.","volume":"68","author":"Ussher","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"B137","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ar.22646","article-title":"Diabetic basement membrane thickening does not occur in myocardial capillaries of transgenic mice when metallothionein is overexpressed in cardiac myocytes.","volume":"296","author":"Velic","year":"2013","journal-title":"Anat. Rec."},{"key":"B138","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1093\/cvr\/cvt125","article-title":"Defective Nrf2-dependent redox signalling contributes to microvascular dysfunction in type 2 diabetes.","volume":"100","author":"Velmurugan","year":"2013","journal-title":"Cardiovasc. Res."},{"key":"B139","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1136\/hrt.2003.020842","article-title":"Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes.","volume":"90","author":"von Bibra","year":"2004","journal-title":"Heart"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/1253425","article-title":"New antihyperglycemic drugs and heart failure: synopsis of basic and clinical data.","volume":"2017","author":"von Lewinski","year":"2017","journal-title":"Biomed Res. Int."},{"key":"B141","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2147\/VHRM.S11681","article-title":"Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies.","volume":"6","author":"Voulgari","year":"2010","journal-title":"Vasc. Health Risk Manag."},{"key":"B142","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.yjmcc.2015.09.018","article-title":"Exenatide exerts a PKA-dependent positive inotropic effect in human atrial myocardium: GLP-1R mediated effects in human myocardium.","author":"Wallner","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B143","first-page":"2709","article-title":"Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes.","volume":"51","author":"Way","year":"2002","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B144","doi-asserted-by":"publisher","first-page":"641","DOI":"10.2337\/db06-1163","article-title":"Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism.","volume":"56","author":"Westermann","year":"2007","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B145","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes.","volume":"369","author":"White","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"B146","doi-asserted-by":"publisher","first-page":"13936","DOI":"10.1074\/jbc.M112.445841","article-title":"Identifying natural substrates for dipeptidyl peptidases 8 and 9 using terminal amine isotopic labeling of substrates (TAILS) reveals in vivo roles in cellular homeostasis and energy metabolism.","volume":"288","author":"Wilson","year":"2013","journal-title":"J. Biol. Chem."},{"key":"B147","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.cardfail.2012.07.009","article-title":"Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy.","volume":"18","author":"Witteles","year":"2012","journal-title":"J. Card. Fail."},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-84","article-title":"Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.","volume":"11","author":"Wohlfart","year":"2013","journal-title":"J. Transl. Med."},{"key":"B149","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.bbagen.2011.03.014","article-title":"Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes.","volume":"1820","author":"Yamagishi","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"B150","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.2337\/diabetes.54.11.3082","article-title":"Effects of diabetes on ryanodine receptor Ca release channel (RyR2) and Ca2+ homeostasis in rat heart.","volume":"54","author":"Yaras","year":"2005","journal-title":"Diabetes Metab. Res. Rev."},{"key":"B151","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ijcard.2015.10.019","article-title":"Involvement of long noncoding RNA MALAT1 in the pathogenesis of diabetic cardiomyopathy.","volume":"202","author":"Zhang","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"B152","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.yjmcc.2014.09.022","article-title":"Sulforaphane prevents the development of cardiomyopathy in type 2 diabetic mice probably by reversing oxidative stress-induced inhibition of LKB1\/AMPK pathway.","volume":"77","author":"Zhang","year":"2014","journal-title":"J. Mol. Cell. Cardiol."},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.321","article-title":"lncRNA MIAT functions as a competing endogenous RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy.","volume":"8","author":"Zhou","year":"2017","journal-title":"Cell Death Dis."},{"key":"B154","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B155","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death.","volume":"363","author":"Zoungas","year":"2010","journal-title":"N. Engl. J. Med."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2018.01514\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T22:22:47Z","timestamp":1775254967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2018.01514\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,30]]},"references-count":155,"alternative-id":["10.3389\/fphys.2018.01514"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2018.01514","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,30]]},"article-number":"1514"}}